• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CBER’s 2021-2025 Strategic Plan Features Advances in Real-World Data

CBER’s 2021-2025 Strategic Plan Features Advances in Real-World Data

March 22, 2021

The FDA’s Center for Biologics Evaluation and Research (CBER) has released a strategic plan for 2021-2025 that outlines how the center will use advances in science and technology to help speed product development.

CBER plans to encourage more use of real-world data (RWD) in regulatory submissions by promoting a standardized format for sponsors. This will allow CBER to better track how real-world evidence is used to “assess effectiveness or safety outcomes in randomized clinical trials or in observational studies,” the center says. The agency is also focused on increasing the use of complex innovative designs in trials, the plan says.

CBER will also urge trial sponsors to develop patient-reported outcome instruments that “can be used in trials to directly measure the effect of a medical treatment by how the patient feels and functions” without the needed for a healthcare provider or clinician. “Integrating these measures into the design of a clinical study is one way to enhance a patient’s assessment of a medical product’s effects,” the center says.

In addition, the CBER flags its increased use of new technologies during product reviews and its greater reliance on modeling and simulations.

Model-Informed Drug Development approaches, for example, “can improve clinical trial efficiency, increase the probability of regulatory success and optimize drug dosing/therapeutic individualization in the absence of dedicated trials,” the center says. And once a product is approved, artificial intelligence and machine learning can be used to comb through RWD to improve postmarket surveillance for adverse events.

Read the 2021-2025 Strategic Plan here: https://bit.ly/3scgA1K.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing